Inflammatory Bowel Disease Treatment Market Size Analysis - Market Share, Forecast Trends and Outlook Report (2025-2034)
Description
The inflammatory bowel disease treatment market was valued at USD 19.60 Billion in 2024, driven by the increasing prevalence of inflammatory bowel disease across the 8 major markets. The market is anticipated to grow at a CAGR of 5.71% during the forecast period of 2025-2034, with the values likely to reach USD 34.15 Billion by 2034.
Inflammatory Bowel Disease Treatment Market Overview
Inflammatory bowel disease is a set of two disorders (ulcerative colitis and Crohn’s disease) causing chronic inflammation in the digestive system (particularly intestines). Common symptoms include abdominal pain, diarrhea, appetite loss, bloating, or blood in the stool. Immune system malfunction and gene mutation may be general causes of the disease. Inflammatory bowel disease treatment revolves around reducing inflammation. Medical professionals use anti-inflammatory drugs as a primary treatment source. Immune system suppressors, antibiotics, biologics, and surgery in extreme cases are common treatment methods.
With the rising prevalence of Crohn's disease and ulcerative colitis coupled with increasing government support for research, the inflammatory bowel disease treatment market is witnessing significant growth. Although the explicit etiopathogenesis of inflammatory bowel disease is still vague, researchers have been able to develop effective drugs and treatment alternatives with the help of a greater understanding of digestive physiology and technical advancements in biotechnology. This has fueled the demand for this treatment market further. Moreover, the increasing number of drugs under clinical trials and the rising popularity of pre-biotic and pro-biotic food products are likely to elevate the market value in the coming years.
Inflammatory Bowel Disease Treatment Market Growth Drivers
Increasing Prevalence of Inflammatory Bowel Disease Drives Market Growth
Inflammatory bowel disease poses a serious global health concern, affecting over 0.3% of the world population. In the United States, the prevalence of the disease is reported to be between 2.4 and 3.1 million, with the burden differing across groups within the population. Thus, the increasing prevalence of inflammatory bowel disease is one of the primary drivers of the market, which is propelling the demand for effective treatment options. Additionally, heightened public awareness and the advances in diagnostic capabilities are poised to support market growth.
Inflammatory Bowel Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Mergers and Acquisitions Events to Affect the Market Landscape Significantly
To meet the rising market demand, healthcare giants across the 8 major markets are undergoing significant mergers and acquisitions. For instance, in October 2023, Sanofi and Teva announced their exclusive partnership to deliver inflammatory bowel disease treatment drugs. The collaboration combines Teva’s anti-TL1A therapy (developed to treat Crohn’s disease and ulcerative colitis) with Sanofi’s immunology strategy for exploring the action mechanism of chronic inflammatory diseases. The companies are aiming to commercialize and develop the TEV’574 drug together, which is currently in phase 2 trials.
In addition, Merck has also announced a USD 10.8 billion buy-out of Prometheus Biosciences, in order to access their anti-TL1A monoclonal antibody (mAb), which is entering a Phase III placebo-controlled study for Crohn’s and ulcerative colitis (UC). Such strategic mergers and acquisitions are expected to aid in market expansion.
Growth in Drug Approvals to Elevate Inflammatory Bowel Disease Treatment Market Value
In June 2024, American pharmaceutical company AbbVie announced that its interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab-rzaa) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis in adults. The regulatory approval also marked the expansion of AbbVie’s portfolio across inflammatory bowel disease treatments, which is poised to contribute to the market growth.
Growing Use of Biologics and Biosimilars to Augment the Inflammatory Bowel Disease Treatment Market Demand
Biologic drugs are widely used in the treatment of inflammatory bowel disease due to their ability to target specific molecules involved in the immune response. In addition, the market is experiencing a growing adoption of biosimilars, which are similar versions of biologics but are typically more affordable. Hence, the rising use of biologics and biosimilars is set to amplify market demand in the coming years.
Increasing Investment in Research and Development to Boost Inflammatory Bowel Disease Treatment Market Size
One of the major market trends is the rising investments in the development of novel therapies for inflammatory bowel disease. Leading pharmaceutical companies are focused on advancing pipeline drugs targeting new pathways, such as microbiome modulation, stem cell therapies, and gene editing techniques, which is anticipated to boost the market size in the forecast period.
Inflammatory Bowel Disease Treatment Market Segmentation
Market Breakup by Disease Indication
The Drug Class Segment Holds a Substantial Market Share
Based on the drug class, the market is segmented into IL inhibitors, TNF inhibitors, anti-integrin, JAK inhibitors, corticosteroids, ASA drugs, and others. TNF (tumor necrosis factor) inhibitors hold a high market value owing to their widespread use in the treatment of both Crohn's disease and ulcerative colitis. These drugs have exhibited high efficacy in managing moderate to severe inflammatory bowel disease, especially in cases where the patients do not respond to conventional therapies.
Inflammatory Bowel Disease Treatment Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share, which can be attributed to the presence of an advanced healthcare infrastructure and high healthcare expenditure which allows the early access and adoption of newer biologics, small molecules, and other innovative treatments in the region. The availability of several biosimilars for inflammatory bowel disease also benefits the market growth. Moreover, the presence of strong regulatory support for novel drug approvals is one of the key factors aiding the market expansion in the country.
Leading Players in the Inflammatory Bowel Disease Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer is a key player in the market, boasting a strong portfolio of drugs including its biologic Xeljanz (tofacitinib), a JAK inhibitor for the treatment of ulcerative colitis. The company is focused on expanding its biologics and targeted therapies pipeline for inflammatory bowel disease through strategic partnerships.
GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (GSK) has a prominent presence in the market and is investing in research and development to improve its biologics portfolio. The company is engaged in exploring immune-modulating therapies for combatting inflammatory bowel disease.
Novartis AG
Swiss multinational pharmaceutical corporation Novartis is a dominant player in the market and is working towards expanding indications for its existing drugs and developing new treatments aimed at improving long-term outcomes for inflammatory bowel disease.
Mylan N.V.
Mylan N.V., a generic and specialty pharmaceuticals company, is headquartered in Pennsylvania, United States. The company plays a significant role in improving access to biosimilars, especially in regions that are seeking cost-effective healthcare solutions for inflammatory bowel disease.
Other key players in the market include Teva Pharmaceutical Industries Ltd., Sanofi SA, AstraZeneca Plc, Janssen Pharmaceuticals Inc., Merck & Co., Baxter International Inc., Bayer AG, Eli Lilly and Company, AbbVie Inc., and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in the Inflammatory Bowel Disease Treatment Market Report
Inflammatory Bowel Disease Treatment Market Overview
Inflammatory bowel disease is a set of two disorders (ulcerative colitis and Crohn’s disease) causing chronic inflammation in the digestive system (particularly intestines). Common symptoms include abdominal pain, diarrhea, appetite loss, bloating, or blood in the stool. Immune system malfunction and gene mutation may be general causes of the disease. Inflammatory bowel disease treatment revolves around reducing inflammation. Medical professionals use anti-inflammatory drugs as a primary treatment source. Immune system suppressors, antibiotics, biologics, and surgery in extreme cases are common treatment methods.
With the rising prevalence of Crohn's disease and ulcerative colitis coupled with increasing government support for research, the inflammatory bowel disease treatment market is witnessing significant growth. Although the explicit etiopathogenesis of inflammatory bowel disease is still vague, researchers have been able to develop effective drugs and treatment alternatives with the help of a greater understanding of digestive physiology and technical advancements in biotechnology. This has fueled the demand for this treatment market further. Moreover, the increasing number of drugs under clinical trials and the rising popularity of pre-biotic and pro-biotic food products are likely to elevate the market value in the coming years.
Inflammatory Bowel Disease Treatment Market Growth Drivers
Increasing Prevalence of Inflammatory Bowel Disease Drives Market Growth
Inflammatory bowel disease poses a serious global health concern, affecting over 0.3% of the world population. In the United States, the prevalence of the disease is reported to be between 2.4 and 3.1 million, with the burden differing across groups within the population. Thus, the increasing prevalence of inflammatory bowel disease is one of the primary drivers of the market, which is propelling the demand for effective treatment options. Additionally, heightened public awareness and the advances in diagnostic capabilities are poised to support market growth.
Inflammatory Bowel Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Mergers and Acquisitions Events to Affect the Market Landscape Significantly
To meet the rising market demand, healthcare giants across the 8 major markets are undergoing significant mergers and acquisitions. For instance, in October 2023, Sanofi and Teva announced their exclusive partnership to deliver inflammatory bowel disease treatment drugs. The collaboration combines Teva’s anti-TL1A therapy (developed to treat Crohn’s disease and ulcerative colitis) with Sanofi’s immunology strategy for exploring the action mechanism of chronic inflammatory diseases. The companies are aiming to commercialize and develop the TEV’574 drug together, which is currently in phase 2 trials.
In addition, Merck has also announced a USD 10.8 billion buy-out of Prometheus Biosciences, in order to access their anti-TL1A monoclonal antibody (mAb), which is entering a Phase III placebo-controlled study for Crohn’s and ulcerative colitis (UC). Such strategic mergers and acquisitions are expected to aid in market expansion.
Growth in Drug Approvals to Elevate Inflammatory Bowel Disease Treatment Market Value
In June 2024, American pharmaceutical company AbbVie announced that its interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab-rzaa) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis in adults. The regulatory approval also marked the expansion of AbbVie’s portfolio across inflammatory bowel disease treatments, which is poised to contribute to the market growth.
Growing Use of Biologics and Biosimilars to Augment the Inflammatory Bowel Disease Treatment Market Demand
Biologic drugs are widely used in the treatment of inflammatory bowel disease due to their ability to target specific molecules involved in the immune response. In addition, the market is experiencing a growing adoption of biosimilars, which are similar versions of biologics but are typically more affordable. Hence, the rising use of biologics and biosimilars is set to amplify market demand in the coming years.
Increasing Investment in Research and Development to Boost Inflammatory Bowel Disease Treatment Market Size
One of the major market trends is the rising investments in the development of novel therapies for inflammatory bowel disease. Leading pharmaceutical companies are focused on advancing pipeline drugs targeting new pathways, such as microbiome modulation, stem cell therapies, and gene editing techniques, which is anticipated to boost the market size in the forecast period.
Inflammatory Bowel Disease Treatment Market Segmentation
Market Breakup by Disease Indication
- Ulcerative Colitis
- Crohn’s Disease
- IL Inhibitors
- TNF Inhibitors
- Anti-integrin
- JAK Inhibitors
- Corticosteroids
- ASA Drugs
- Others
- Oral
- Injectable
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
The Drug Class Segment Holds a Substantial Market Share
Based on the drug class, the market is segmented into IL inhibitors, TNF inhibitors, anti-integrin, JAK inhibitors, corticosteroids, ASA drugs, and others. TNF (tumor necrosis factor) inhibitors hold a high market value owing to their widespread use in the treatment of both Crohn's disease and ulcerative colitis. These drugs have exhibited high efficacy in managing moderate to severe inflammatory bowel disease, especially in cases where the patients do not respond to conventional therapies.
Inflammatory Bowel Disease Treatment Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share, which can be attributed to the presence of an advanced healthcare infrastructure and high healthcare expenditure which allows the early access and adoption of newer biologics, small molecules, and other innovative treatments in the region. The availability of several biosimilars for inflammatory bowel disease also benefits the market growth. Moreover, the presence of strong regulatory support for novel drug approvals is one of the key factors aiding the market expansion in the country.
Leading Players in the Inflammatory Bowel Disease Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer is a key player in the market, boasting a strong portfolio of drugs including its biologic Xeljanz (tofacitinib), a JAK inhibitor for the treatment of ulcerative colitis. The company is focused on expanding its biologics and targeted therapies pipeline for inflammatory bowel disease through strategic partnerships.
GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (GSK) has a prominent presence in the market and is investing in research and development to improve its biologics portfolio. The company is engaged in exploring immune-modulating therapies for combatting inflammatory bowel disease.
Novartis AG
Swiss multinational pharmaceutical corporation Novartis is a dominant player in the market and is working towards expanding indications for its existing drugs and developing new treatments aimed at improving long-term outcomes for inflammatory bowel disease.
Mylan N.V.
Mylan N.V., a generic and specialty pharmaceuticals company, is headquartered in Pennsylvania, United States. The company plays a significant role in improving access to biosimilars, especially in regions that are seeking cost-effective healthcare solutions for inflammatory bowel disease.
Other key players in the market include Teva Pharmaceutical Industries Ltd., Sanofi SA, AstraZeneca Plc, Janssen Pharmaceuticals Inc., Merck & Co., Baxter International Inc., Bayer AG, Eli Lilly and Company, AbbVie Inc., and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in the Inflammatory Bowel Disease Treatment Market Report
- What was the inflammatory bowel disease treatment market value in 2024?
- What is the inflammatory bowel disease treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on disease indication?
- What is the market breakup based on drug class?
- What is the market breakup by route of administration?
- What are the major distribution channels in the market?
- What are the major factors aiding the inflammatory bowel disease treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of inflammatory bowel disease affect the market landscape?
- What are the major inflammatory bowel disease treatment market trends?
- How do the rising investments in research and development impact the market size?
- Which disease indication will dominate the market share?
- Which drug class is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which distribution channel is projected to contribute to the highest market growth?
- Who are the key players involved in the inflammatory bowel disease treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Inflammatory Bowel Disease Treatment Market Overview: 8 Major Market
- 3.1 Inflammatory Bowel Disease Treatment Market Historical Value (2018-2024)
- 3.2 Inflammatory Bowel Disease Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Inflammatory Bowel: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Inflammatory Bowel Disease Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Inflammatory Bowel Disease Treatment Market Landscape: 8 Major Market*
- 8.1 Inflammatory Bowel Disease Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Inflammatory Bowel Disease Treatment Market: Product Landscape
- 8.2.1 Analysis by Disease Indication
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 9 Inflammatory Bowel Disease Treatment Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Inflammatory Bowel Disease Treatment Market: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Inflammatory Bowel Disease Treatment Market Segmentation: 8 Major Markets
- 12.1 Inflammatory Bowel Disease Treatment Market (2018-2034) by Disease Indication
- 12.1.1 Market Overview
- 12.1.2 Ulcerative Colitis
- 12.1.3 Crohn’s Disease
- 12.2 Inflammatory Bowel Disease Treatment Market (2018-2034) by Drug Class
- 12.2.1 Market Overview
- 12.2.2 IL Inhibitors
- 12.2.3 TNF Inhibitors
- 12.2.4 Anti-integrin
- 12.2.5 JAK Inhibitors
- 12.2.6 Corticosteroids
- 12.2.7 ASA Drugs
- 12.2.8 Others
- 12.3 Inflammatory Bowel Disease Treatment Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Injectable
- 12.4 Inflammatory Bowel Disease Treatment Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacy
- 12.4.3 Online Pharmacy
- 12.4.4 Retail Pharmacy
- 12.5 Inflammatory Bowel Disease Treatment Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Inflammatory Bowel Disease Treatment Market (218-2034)
- 13.1 United States Inflammatory Bowel Disease Treatment Market Historical Value (2018-2024)
- 13.2 United States Inflammatory Bowel Disease Treatment Market Forecast Value (2025-2034)
- 13.3 United States Inflammatory Bowel Disease Treatment Market (2018-2034) by Disease Indication
- 13.3.1 Market Overview
- 13.3.2 Ulcerative Colitis
- 13.3.3 Crohn’s Disease
- 13.4 United States Inflammatory Bowel Disease Treatment Market (2018-2034) by Drug Class
- 13.4.1 Market Overview
- 13.4.2 IL Inhibitors
- 13.4.3 TNF Inhibitors
- 13.4.4 Anti-integrin
- 13.4.5 JAK Inhibitors
- 13.4.6 Corticosteroids
- 13.4.7 ASA Drugs
- 13.4.8 Others
- 13.5 United States Inflammatory Bowel Disease Treatment Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Injectable
- 13.6 United States Inflammatory Bowel Disease Treatment Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacy
- 13.6.3 Online Pharmacy
- 13.6.4 Retail Pharmacy
- 14 Retail PharmacyEU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market (2018-2034) by Disease Indication
- 14.3.1 Market Overview
- 14.3.2 Ulcerative Colitis
- 14.3.3 Crohn’s Disease
- 14.4 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market (2018-2034) by Drug Class
- 14.4.1 Market Overview
- 14.4.2 IL Inhibitors
- 14.4.3 TNF Inhibitors
- 14.4.4 Anti-integrin
- 14.4.5 JAK Inhibitors
- 14.4.6 Corticosteroids
- 14.4.7 ASA Drugs
- 14.4.8 Others
- 14.5 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Injectable
- 14.6 EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market (2018-2034) by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Hospital Pharmacy
- 14.6.3 Online Pharmacy
- 14.6.4 Retail Pharmacy
- 15 Japan Inflammatory Bowel Disease Treatment Market
- 15.1 Japan Inflammatory Bowel Disease Treatment Market Historical Value (2018-2024)
- 15.2 Japan Inflammatory Bowel Disease Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Inflammatory Bowel Disease Treatment Market (2018-2034) by Disease Indication
- 15.3.1 Market Overview
- 15.3.2 Ulcerative Colitis
- 15.3.3 Crohn’s Disease
- 15.4 Japan Inflammatory Bowel Disease Treatment Market (2018-2034) by Drug Class
- 15.4.1 Market Overview
- 15.4.2 IL Inhibitors
- 15.4.3 TNF Inhibitors
- 15.4.4 Anti-integrin
- 15.4.5 JAK Inhibitors
- 15.4.6 Corticosteroids
- 15.4.7 ASA Drugs
- 15.4.8 Others
- 15.5 Japan Inflammatory Bowel Disease Treatment Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Injectable
- 15.6 Japan Inflammatory Bowel Disease Treatment Market (2018-2034) by Distribution Channel
- 15.6.1 Market Overview
- 15.6.2 Hospital Pharmacy
- 15.6.3 Online Pharmacy
- 15.6.4 Retail Pharmacy
- 16 India Inflammatory Bowel Disease Treatment Market
- 16.1 India Inflammatory Bowel Disease Treatment Market Historical Value (2018-2024)
- 16.2 India Inflammatory Bowel Disease Treatment Market Forecast Value (2025-2034)
- 16.3 India Inflammatory Bowel Disease Treatment Market (2018-2034) by Disease Indication
- 16.3.1 Market Overview
- 16.3.2 Ulcerative Colitis
- 16.3.3 Crohn’s Disease
- 16.4 India Inflammatory Bowel Disease Treatment Market (2018-2034) by Drug Class
- 16.4.1 Market Overview
- 16.4.2 IL Inhibitors
- 16.4.3 TNF Inhibitors
- 16.4.4 Anti-integrin
- 16.4.5 JAK Inhibitors
- 16.4.6 Corticosteroids
- 16.4.7 ASA Drugs
- 16.4.8 Others
- 16.5 India Inflammatory Bowel Disease Treatment Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Injectable
- 16.6 India Inflammatory Bowel Disease Treatment Market (2018-2034) by Distribution Channel
- 16.6.1 Market Overview
- 16.6.2 Hospital Pharmacy
- 16.6.3 Online Pharmacy
- 16.6.4 Retail Pharmacy
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Pfizer Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 GlaxoSmithKline plc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Mylan N.V.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Teva Pharmaceutical Industries Ltd.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Sanofi SA
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 AstraZeneca Plc
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Janssen Pharmaceuticals Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 Merck & Co.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 Baxter International Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 23.12 Bayer AG
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Developments
- 23.12.5 Certifications
- 23.13 Eli Lilly and Company
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Company News and Developments
- 23.13.5 Certifications
- 23.14 Sun Pharmaceutical Industries Ltd.
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Company News and Developments
- 23.14.5 Certifications
- 23.15 AbbVie Inc.
- 23.15.1 Financial Analysis
- 23.15.2 Product Portfolio
- 23.15.3 Demographic Reach and Achievements
- 23.15.4 Company News and Developments
- 23.15.5 Certifications
- 24 Inflammatory Bowel Disease Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
